Cargando…
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
BACKGROUND: Etanercept (ETN) is widely used tumour necrosis factor (TNF) blocker in the treatment of juvenile idiopathic arthritis (JIA) when traditional synthetic disease modifying antirheumatic drug (sDMARD) therapy is not sufficient. There is limited information about the effects of methotrexate...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035115/ https://www.ncbi.nlm.nih.gov/pubmed/36949461 http://dx.doi.org/10.1186/s12969-023-00801-2 |
_version_ | 1784911350828367872 |
---|---|
author | Levälampi, Tiina Kärki, Johanna Rebane, Katariina Vähäsalo, Paula Malin, Merja Kröger, Liisa Grönlund, Minna-Maija Backström, Maria Pohjankoski, Heini Kautiainen, Hannu Jokiranta, Sakari Aalto, Kristiina |
author_facet | Levälampi, Tiina Kärki, Johanna Rebane, Katariina Vähäsalo, Paula Malin, Merja Kröger, Liisa Grönlund, Minna-Maija Backström, Maria Pohjankoski, Heini Kautiainen, Hannu Jokiranta, Sakari Aalto, Kristiina |
author_sort | Levälampi, Tiina |
collection | PubMed |
description | BACKGROUND: Etanercept (ETN) is widely used tumour necrosis factor (TNF) blocker in the treatment of juvenile idiopathic arthritis (JIA) when traditional synthetic disease modifying antirheumatic drug (sDMARD) therapy is not sufficient. There is limited information about the effects of methotrexate (MTX) on serum ETN concentration in children with JIA. We aimed to investigate whether ETN dose and concomitant MTX would effect ETN serum trough levels in JIA patients, and whether concomitant MTX have an influence on the clinical response in patients with JIA receiving ETN. METHODS: In this study, we collected the medical record data of 180 JIA patients from eight Finnish pediatric rheumatological centres. All these patients were treated with ETN monotherapy or combination therapy with DMARD. To evaluate the ETN concentrations, blood samples of the patients were collected between injections right before the subsequent drug. Free ETN level was measured from serum. RESULTS: Ninety-seven (54%) of the patients used concomitant MTX, and 83 (46%) received either ETN monotherapy or used sDMARDs other than MTX. A significant correlation was noted between ETN dose and drug level [r = 0.45 (95% CI: 0.33–0.56)]. The ETN dose and serum drug level were correlated (p = 0.030) in both subgroups – in MTX group [r = 0.35 (95% CI: 0.14–0.52)] and in non-MTX group [r = 0.54 (95% CI: 0.39–0.67)]. CONCLUSION: In the present study, we found that concomitant MTX had no effect on serum ETN concentration or on clinical response. In addition, a significant correlation was detected between ETN dose and ETN concentration. |
format | Online Article Text |
id | pubmed-10035115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100351152023-03-24 Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study Levälampi, Tiina Kärki, Johanna Rebane, Katariina Vähäsalo, Paula Malin, Merja Kröger, Liisa Grönlund, Minna-Maija Backström, Maria Pohjankoski, Heini Kautiainen, Hannu Jokiranta, Sakari Aalto, Kristiina Pediatr Rheumatol Online J Research Article BACKGROUND: Etanercept (ETN) is widely used tumour necrosis factor (TNF) blocker in the treatment of juvenile idiopathic arthritis (JIA) when traditional synthetic disease modifying antirheumatic drug (sDMARD) therapy is not sufficient. There is limited information about the effects of methotrexate (MTX) on serum ETN concentration in children with JIA. We aimed to investigate whether ETN dose and concomitant MTX would effect ETN serum trough levels in JIA patients, and whether concomitant MTX have an influence on the clinical response in patients with JIA receiving ETN. METHODS: In this study, we collected the medical record data of 180 JIA patients from eight Finnish pediatric rheumatological centres. All these patients were treated with ETN monotherapy or combination therapy with DMARD. To evaluate the ETN concentrations, blood samples of the patients were collected between injections right before the subsequent drug. Free ETN level was measured from serum. RESULTS: Ninety-seven (54%) of the patients used concomitant MTX, and 83 (46%) received either ETN monotherapy or used sDMARDs other than MTX. A significant correlation was noted between ETN dose and drug level [r = 0.45 (95% CI: 0.33–0.56)]. The ETN dose and serum drug level were correlated (p = 0.030) in both subgroups – in MTX group [r = 0.35 (95% CI: 0.14–0.52)] and in non-MTX group [r = 0.54 (95% CI: 0.39–0.67)]. CONCLUSION: In the present study, we found that concomitant MTX had no effect on serum ETN concentration or on clinical response. In addition, a significant correlation was detected between ETN dose and ETN concentration. BioMed Central 2023-03-22 /pmc/articles/PMC10035115/ /pubmed/36949461 http://dx.doi.org/10.1186/s12969-023-00801-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Levälampi, Tiina Kärki, Johanna Rebane, Katariina Vähäsalo, Paula Malin, Merja Kröger, Liisa Grönlund, Minna-Maija Backström, Maria Pohjankoski, Heini Kautiainen, Hannu Jokiranta, Sakari Aalto, Kristiina Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study |
title | Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study |
title_full | Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study |
title_fullStr | Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study |
title_full_unstemmed | Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study |
title_short | Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study |
title_sort | etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035115/ https://www.ncbi.nlm.nih.gov/pubmed/36949461 http://dx.doi.org/10.1186/s12969-023-00801-2 |
work_keys_str_mv | AT levalampitiina etanerceptforpatientswithjuvenileidiopathicarthritisdruglevelsandinfluenceofconcomitantmethotrexateobservationalstudy AT karkijohanna etanerceptforpatientswithjuvenileidiopathicarthritisdruglevelsandinfluenceofconcomitantmethotrexateobservationalstudy AT rebanekatariina etanerceptforpatientswithjuvenileidiopathicarthritisdruglevelsandinfluenceofconcomitantmethotrexateobservationalstudy AT vahasalopaula etanerceptforpatientswithjuvenileidiopathicarthritisdruglevelsandinfluenceofconcomitantmethotrexateobservationalstudy AT malinmerja etanerceptforpatientswithjuvenileidiopathicarthritisdruglevelsandinfluenceofconcomitantmethotrexateobservationalstudy AT krogerliisa etanerceptforpatientswithjuvenileidiopathicarthritisdruglevelsandinfluenceofconcomitantmethotrexateobservationalstudy AT gronlundminnamaija etanerceptforpatientswithjuvenileidiopathicarthritisdruglevelsandinfluenceofconcomitantmethotrexateobservationalstudy AT backstrommaria etanerceptforpatientswithjuvenileidiopathicarthritisdruglevelsandinfluenceofconcomitantmethotrexateobservationalstudy AT pohjankoskiheini etanerceptforpatientswithjuvenileidiopathicarthritisdruglevelsandinfluenceofconcomitantmethotrexateobservationalstudy AT kautiainenhannu etanerceptforpatientswithjuvenileidiopathicarthritisdruglevelsandinfluenceofconcomitantmethotrexateobservationalstudy AT jokirantasakari etanerceptforpatientswithjuvenileidiopathicarthritisdruglevelsandinfluenceofconcomitantmethotrexateobservationalstudy AT aaltokristiina etanerceptforpatientswithjuvenileidiopathicarthritisdruglevelsandinfluenceofconcomitantmethotrexateobservationalstudy |